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A neonate presented with mucopolysaccharidosis-like phenotypic expression and 
typical signs of dysostosis multiplex but without urinary excretion of 
glycosaminoglycans. Investigations of lysosomal enzymes in cultured fibroblasts 
revealed a mucolipidosis type 2, known as I-cell disease. We describe the fatal 
course of the patient due to complications of an uncommon dilated cardiomyopathy 
in this rare disease and discuss the pathogenesis. 
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Mucolipidosis type 2 (ML-2; McKusick 252500) is a lysosomal storage disorder and is 
caused by an autosomal recessive inherited defect of N-acetylglucosamine-1-
phosphotransferase (E.C. 2.7.8.17). This cytosolic enzyme is involved in the 
processing of various hydrolases to permit their recognition and subsequent 
internalisation into lysosomes. Defective enzyme function ends in general in 
misrouting of newly synthesised enzymes. Vacuolised lymphocytes and the 
appearance of inclusion bodies in cultured fibroblasts resulted in naming this disorder 
„I-cell-disease”. Affected cells are mostly of mesenchymal origin. Characteristic and 
revealing clinical symptoms are Hurler-like features without mucopolysacchariduria. 
The disorder is slowly progressive with onset at birth and fatal outcome in early 
childhood due to bronchopneumonia or congestive heart failure. Cardiac 
manifestations in systemic storage disorders are common but especially in 
mucolipidosis type 2 there are few reports about involvements of cardiovascular 
system during the first weeks of life. The majority of described patients suffers from 
hypertrophic cardiomyopathy.1 
We report a case with mucolipidosis type 2 complicated by severe dilative 
cardiomyopathy (DCM) which is very rare associated with this lysosomal storage 
disorder and we discuss possible mechanisms of pathogenesis. 
 
Case report 
The female patient of healthy German couples was the first child after an uneventful 
pregnancy and delivery. The newborn was hypotrophic with a birth weight of 2370 g. 
She presented with the following signs and dysmorphisms which implicated infantile 
onset heteroglycanosis: coarse face, gum hyperplasia, rough voice, joint contractions 
and hip luxations. Dysostosis multiplex and a globular heart were X-rays findings at 
the age of 8 weeks (Fig. 1). The roentgenographic appearance of the ribs was 
specific, as well as short and stubby bones of the upper extremities or thoracolumbar 
gibbus of the spine. ECG showed a dilated left ventricle with marginal reduced 
systolic parameters of cardiac function (Tab. 1). 
 
Figure 1 Patient with mucolipidosis type 2 at the age of 9 months 
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Table 1 Echocardiographic findings in the girl with ML-2 before and during 
symptomatic therapy. Normal ranges are given in brackets. Normal values for 
LVEDD were interpolated.8 Abbrevations: FS - fraction shortening, EF – ejection 




Laboratory findings of liver and renal functions including chromosomes showed no 
abnormalities, however there were vacuoles in peripherial white blood cells pointing 
to lysosmal storage disorder. A mucopolysaccharidosis of Hurler-type was presumed 
but several examinations detected no excess of mucopolysaccharides in urine. The 
patient was admitted to outside hospital due to airway infections, failure to thrive and 
poor development for several times during the next 4 months. Regular cardiac 
examinations revealed an increasing tendency of disturbed systolic function with 
dilation of the heart muscle (Tab. 1). At the age of 9 months the patient's condition 
was severely restricted due to signs of cardiac insufficiency with poor feeding, 
sweating, hepatomegaly (2-3 cm) and perioral cyanosis. No specific therapy was 
initiated until transfer to centres for specialised cardiac and metabolic investigations. 
Chest X-ray investigation showed a cardiomegaly (Fig. 2). 
 
ECG clarified marked signs of biventricular hypertrophy with 1st degree 
atrioventricular blockade and disturbed re-excitations. Echocardiographic findings 
were interpreted as a dilative cardiomyopathy with poorly contracting action and 
extremely systolic dysfunction of the left ventricle (Tab. 1). There were no structural 
anomalies in the heart including the valves. Atypic origins of coronary arteries (Bland-
White-Garland-syndrome) as the cause of dilated ventricles were excluded by 
coronarography. Treatment with digitalis, angiotensin-converting-enzyme inhibitor 
and diuretics was started at the age of ten months. Clinical signs of cardiac 
insufficiency disappeared within two weeks and the patient stabilised. But 
pathological echocardiographic findings of cardiac function persisted (Tab. 1). A skin 
biopsy and fibroblast culture was initiated at age of 10 months. Cells grew atypically 
and slowly and showed characteristic granular inclusions suggesting ML-2 (Fig. 3). 
Assays of lysosomal hydrolases in fibroblasts confirmed the diagnosis with low 
enzyme activities between 5 and 10 % of normal range for β -hexosaminidase, β -
galactosidase and arylsulphatase A contrary to 10 to 50-fold increased enzyme 
activities in plasma. Despite of medication and physical therapy the patient's 
condition remained poor due to cardiac dystrophy and resulted in delayed 
psychomotoric development (DQ 55). During an episode of recurrent pulmonary 
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infections the girl died unexpected from an atypical pneumonia, when she was 30 
months old. 
 
Figure 2 Chest X-ray illustrating the cardiomegaly and the broadened spatulate ribs 
at the age of 9months 
 
 
Figure 3 Light microscopy of N-acetylglucosamine-1-phosphotransferase deficient 
fibroblasts with characteristic inclusion bodies (enlargement 250-fold) 
 
 
P Mueller, A Moeckel, and I Daehnert. Severe dilated cardiomyopathy as an unusual finding in a 
young infant with mucolipidosis type 2. Images Paediatr Cardiol. 2006 Oct-Dec; 8(4): 1–6.  
 5 
Discussion 
Dilated cardiomyopathies (DCM) are the most common type of cardiomyopathy in 
early childhood and about 50 % have to be classified as idiopathic variants. In about 
20 % sequals of myocarditis or endocardial fibroelastosis, anomalies of coronary 
arteries or previous therapy with doxorubicin (adriblastin®) lead to secondary DCM.2 
Approximately 30 % are genetic cardiomyopathies of autosomal dominant or X-linked 
inheritance pattern.3,4 DCM is characterised by dilation and impaired contraction of 
the left or both ventricles, whereas hypertrophic forms commonly caused by 
metabolic cardiomyopathies appearing with diastolic dysfunction. Most of the patients 
with ML-2 suffer from hypertrophic cardiomyopathy (HCM) and / or valvular 
thickening and prolapse due to mucolipid storage.5 Only one patient was described 
with dilative cardiomyopathy and endocardial fibroelastosis without signs of cardiac 
insufficiency at the age of 10 weeks.6 Our patient showed classical signs and 
symptoms of Mucolipidosis type 2 with exception of early onset DCM. Diagnosis was 
certainly confirmed with enzyme assays. Data for mutational analysis of the deficient 
enzyme N-acetylglucosamine-1-phosphotransferase are currently not available so 
far. To our knowledge, there are also no further reports of I-cell disease where a 
HCM decompensated and resulted in DCM. Pathomechanisms of this atypical clinical 
phenotype are not fully understood. Mannose-6-phosphates are recognition sites of 
enzymes addressed to lysosomes. Almost all mammalian cells express insulin-like 
growth factor-II / mannose-6-phosphate (IGF-II/Man-6-P) receptors. There is a 
specific developmental pattern and tissue distribution known with highest expression 
rate in the heart and decreasing rates in lung, muscle, liver and lowest rate in the 
brain. This rank order is only consistent with organ manifestations in mucolipidosis 
type 2 with regard to the moderate involvement of the brain which reflects a milder 
psychomotor delay in these patients in relation to other lysosomal storage disorders. 
In the heart, the bifunctional IGF-II/Man-6-P receptor amounts to 1.7 % of total 
protein in extracted tissue. Normally, the binding of IGF-II to the receptor is inhibited 
by acid lysosomal enzymes. This may be understood as a principle of modulation 
between cellular metabolic build up and break down. Because of reduced binding of 
correctly phosphorylated hydrolases an increased binding of IGF-II to the receptor is 
postulated. IGF-II stimulates certain cellular biologic effects: Beside actions on 
glucose metabolism there are influences known on the calcium gating system.7 It 
remains speculative if an excess of IGF-II may lead to an overgrowth of the heart 
coupled with disturbed calcium channeling, mechanoenergetic changes and resulting 
dilation of the heart muscle. From the metabolic point of view it is not clear in detail 
admittedly, why only a few of patients develop this cardiac complication. Thus, we 
suggest that dilated cardiomyopathy presented in coincidental occurrence with ML-2 
by chance in these two patients described up to now.6 
Specific treatments (enzyme replacement therapy) have not been developed 
whereas procedures for prenatal diagnosis are available and genetic counselling can 
be offered in this lysosomal storage disorder. Because of progressive complications 
in nearly all organ systems these patients are still no candidates for heart transplants. 
In order to get prognostic information we advise to perform detailed cardiac 
examinations as essential components of the diagnostic work-up in patients with 
mucolipidosis type 2. 
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